MabTrix

Company Overview

Snapshot

Founded in December 2015, MabTrix operates with 1–10 employees. The company has secured funding across two rounds from two investors. In June 2019, MabTrix received funding from RMGP Biopharma Investment Fund.

Business overview

MabTrix is a preclinical-stage biopharmaceutical company focused on developing a function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD). The company's core technology involves a novel humanized MAb designed to specifically inhibit the enzymatic activity of matrix metalloprotease (MMP) 9 by binding to its catalytic site. This approach, enabled by immunization using a proprietary molecule derived from the catalytic domain, aims to reduce inflammation in IBD patients. The technology was developed and licensed from the Weizmann Institute of Science in Israel, positioning MabTrix within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is MabTrix's primary therapeutic focus?

MabTrix is developing a function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) and orphan forms of the disease.

What is the core technology behind MabTrix's therapeutic approach?

MabTrix's technology involves a novel humanized MAb that specifically inhibits the enzymatic activity of matrix metalloprotease (MMP) 9 by binding to the catalytic site of the activated enzyme. This was enabled by immunization using a proprietary molecule called Zn-tripod.

When was MabTrix founded?

MabTrix was founded in December 2015.

Which institution developed the technology licensed by MabTrix?

The technology utilized by MabTrix was developed in and licensed from the laboratory of Professor Irit Sagi at the Weizmann Institute of Science in Israel.

When did MabTrix last receive funding?

MabTrix last received funding in June 2019 from RMGP Biopharma Investment Fund.